How Infusion Services Became a Private Equity Hotspot with Amber Walsh of McGuireWoods LLP 6-26-26

Summary

Becker Private Equity & Business Podcast
Episode: How Infusion Services Became a Private Equity Hotspot with Amber Walsh of McGuireWoods LLP
Host: Scott Becker
Guest: Amber Walsh, Partner at McGuireWoods LLP
Date: June 26, 2026

---

Episode Overview

Scott Becker sits down with Amber Walsh, a prominent lawyer at the intersection of healthcare and private equity, to discuss why infusion services have become a sought-after sector for private equity investment. Using the recent Single Point–Helix transaction as a case study, Walsh and Becker break down the strategic and industry-wide forces driving sustained interest and deal flow in the infusion therapy space. Listeners gain insights into sector dynamics, private equity trends, and the regulatory challenges unique to these deals.

---

Key Discussion Points and Insights

1. The Single Point–Helix Transaction as a Case Study

• Deal Snapshot:
  • Single Point, backed by DFW Partners, acquired Helix Infusion Services—a company previously owned by TA Associates.
  • Both are private equity-backed; Helix had scaled to 220 infusion therapy or pharmacy sites in 38 states (01:01–02:20).
• Deal Significance:
  • Exemplifies the current trends in healthcare private equity, especially post-pandemic shifts from hospital-based to outpatient and home-based care.
  • Features both scale and a physician management component, differentiating it in the market.

Quote:
"What’s interesting about the deal is that it really exemplifies a lot of the trends that we’ve been following, particularly coming out of the pandemic… It’s kind of this perfect little example of what private equity investors are looking to do and how they’re looking to differentiate themselves."
—Amber Walsh (01:10)

---

2. Drivers of Value in Infusion Services Private Equity

• Outpatient Migration:

  • Huge movement out of hospital-based settings into outpatient clinics, physician offices, and home infusion centers, accelerated by the pandemic.
  • Example: Helix’s model focuses on physician-owned or managed outpatient centers (02:20–03:53).

• Payer and Reimbursement Impact:

  • Private equity’s interest is furthered by the ability to create cost savings for payers.
  • Outpatient/home infusion can save payers 20–40% compared to hospital setting (industry-wide estimate) (04:01–05:53).

Quote:
"Payers … can save anywhere between 20 and 40%. Of course, those are big numbers, those are global. And … that’s what Single Point and Helix talk about as one of the benefits of Helix, certainly consistent with what the industry has been looking at."
—Amber Walsh (04:25)

---

3. Industry Trends and Transaction Environment

• Market Activity:
  • More deals are getting done in 2026, though volumes are not as high as in 2021–2022; market is busy but no longer frenetic (05:53–07:41).
• Deal Characteristics:
  • Frequent double-digit multiples for reported infusion deals.
  • Regulatory complexities are a major consideration—especially Stark Law issues due to the involvement of physician referrals and relationships.

Quote:
"There’s a big regulatory component to the infusion therapy space…there are a lot of physician relationships and referral sources in there. So … the lawyers that worked on that deal diligenced it pretty hard, including from the lender side."
—Amber Walsh (06:30)

---

4. The Intersection with Physician Practice Management (PPM)

• Infusion as an Ancillary Service:
  • The deal model connects ambulatory infusion centers and the practice management world.
  • High-infusion specialties (oncology, GI, rheumatology, immunology) often run both physician practices and infusion platforms, mirroring the ambulatory surgery center (ASC) sector (07:41–09:56).

Quote:
"You see infusion as an ancillary service in a lot of PPM businesses…one of the places where you see a point of connection between physician practice management businesses and the private equity–backed infusion platform."
—Amber Walsh (08:15)

---

5. Synthesis: Why This is a “Classic” PE Deal

• Private Equity on Both Sides:
  • Both buyer and seller had already executed significant scale and growth pre-deal.
• Highly Diligenced:
  • Heavy legal and compliance diligence due to unique risks (referrals, supply chain, drug costs).
• Represents PE Interests:
  • Scale, payer appeal, cost control, and flexible operating models are all on display (09:56–11:01).

Quote:
"This is kind of a quintessential, from what I can tell as an outsider, kind of a quintessential private equity–backed buy in a space that’s really popular right now and therefore I think is worth talking about."
—Amber Walsh (10:39)

---

Notable Quotes & Memorable Moments

• "It exemplifies a lot of the trends that we've been following for the past couple of years … kind of this perfect little example of what private equity investors are looking to do." —Amber Walsh (01:10)
• "Payers ... can save anywhere between 20 and 40%..." —Amber Walsh (04:25)
• "It has a lot of features that ... private equity investors are looking at when they're growing a platform, selling a platform, hoping that it's going to be able to achieve what it needs to achieve." —Amber Walsh (10:06)
• Repeated use of "fascinating" by Scott Becker, signifying his engagement and enthusiasm about the sector evolution (throughout).

---

Timestamps for Important Segments

• 00:30 – Introduction, guest background
• 01:01 – Overview of the Single Point–Helix transaction
• 02:20 – Structure of Helix and its footprint/ownership model
• 03:53 – Future for Helix post-transaction
• 04:25 – Payer dynamics and cost savings
• 05:53 – PE activity levels and deal environments in 2026
• 06:30 – Regulatory challenges in infusion deals
• 08:11 – The role of infusion in physician practice management
• 09:56 – What makes this a “classic” private equity-backed deal

---

Summary of Takeaways

• Infusion therapy is a prime target for private equity due to reimbursement trends, outpatient migration, and scalable business models focused on cost-effective care.
• Strategic deals feature scale, management of provider relationships, and a heavy focus on compliance–especially around referral rules and reimbursement.
• The infusion therapy space mirrors broader trends seen in specialty care and ambulatory services, creating recurring playbooks for private equity investors.
• Regulatory scrutiny and payer alignment are essential for value creation and sustainability of these platforms.

---

For listeners interested in the intersection of healthcare, private equity, and operational trends, this episode offers a sharp, practitioner’s view of why and how certain healthcare niches—like infusion services—become PE hotspots.

Transcript

[A]

The 2026 FIFA World cup meal at McDonald's is underway with one of nine legendary cups in the lineup. Christian Pulisic, David Beckham, Lamine Yamal, Ronald Dinho, Thierry Henry, Son, Hyung Min, Alphonso Davies, Santi Jimenez. And between the posts, it's Grimace. Get one of nine collectible cups with a FIFA World cup meal at participating McDonald's for a limited time while supplies last. All rights reserved. 20:26 McDonald's at FIFA World Cup 20:26

[B]

this is Scott with the Becker Business and the Becker Private Equity Podcast. We're visiting today with Amber Walsh who's a brilliant lawyer at the intersection of healthcare and private equity. She's going to talk to us today about several things to know about a specific transaction. Amber, let me ask you to tee it up and tell us about the Single Point Helix transaction and what makes it so interesting and then talk us through what people should know about this and why it's impactful.

[C]

Yeah, thank you, Scott. Happy to be here. So a week ago today, Single Point, which is backed by DFW Partners, announced that it had acquired Helix Infusion Services. Helix was formerly owned by TA Associates and what's interesting about the deal is that it really exemplifies the a lot of the trends that we've been following for the past couple of years, particularly coming out of the pandemic. And our firm didn't work on the deal. I'm familiar with all the players but we didn't work on the deal. So I'm not commenting on the players at all. But I am really interested in several facets of the deal that make it kind of this perfect little example of of what private equity investors are looking to do and grow and how they're looking to differentiate themselves not just within the infusion therapy space, which is what this Helix deal was, but kind of across the board.

[B]

Well, thank you. And talk to us about, maybe give us a little context in the deal but also talk to us about what are some of those lessons that are broader for private equity.

[C]

Yeah, so Single Point was already in the infusion pharmacy or infusion therapy space. They had done a couple of add on acquisitions. Helix, also private equity based, had also grown through a series of acquisitions and de novo builds Helix at the time of the deal and it's only been a week so presumably not much has changed. Had managed or owned 220 infusion therapy or infusion pharmacy sites across 38 states. So it's kind of that perfect example of the scaled platform and those sites and this is another feature of it that makes it so on point for what so many investors are looking at right now. Those sites were dominantly, if not exclusively physician owned and physician office based, where healing provided management services or home based, or at least kind of walk in outpatient based. They were not hospital based. And that's been one of the big drivers, obviously the pandemic. We all know that the pandemic was a huge boost for a lot of things that were previously thought of as a hospital based service moving into an outpatient basis. And the Helix platform and what they'd grown over the past several years is kind of a perfect example of that.

[B]

Fascinating. And so where does this take Helix going forward? What does this look like going forward?

[C]

Yeah, so according to their announcement, and this is pretty common, the announcement for the single point side, the buy side, is that it gives in this platform, including with the physician management component of it that I don't think they previously had, it gives them not just the scale across a lot more states, but it also gives them this model where managed physician own centers for a portion of what they do. The other thing that they talked about in the press release, which is not at all surprising, we've seen this kind of across the board in infusion pharmacy for the past several years, which is the reimbursement impact with payers. So payers, you'll see some quotes that as payers are able to move their members from the hospital setting for infusion to an outpatient or home setting that they can save anywhere between 20 and 40%. Of course those are big numbers, those are global. And I don't know if that's what Helix was achieving for payers, but certainly what single point and Helix talk about as one of the benefits of Helix is certainly consistent with what the industry has been looking at. And of course we see that outside of infusion therapy too, which is just that migration, but also the ability to have a payer and reimbursement play and make yourself attractive as a platform to where you're not just attractive because you're adding on more and more sites, you are attractive because you're able to lower the overall cost of care and be part of the win win solution.

[B]

Fascinating. Fascinating. And is this, this acquisition, I don't know how big an acquisition of it is. Is this an indication that there's just more private equity money flowing towards health care and deals getting done again, or can you not generalize towards that point?

[C]

Yeah, the deal terms are undisclosed. Just generally in infusion therapy, when the deals get reported, they're often in double digit multiples. But our perception is the feeling that we've had as a firm for certainly most of 2026 is that yes, there are more deals getting done. It's not high volume, it's not frenetic, it's not like it was in 2021 and 2022. Deals are getting done, the reins are getting loosened and some of the deals are very large. But the other feature of those, some of the deals that we're seeing, which I think is also probably consistent with Helix, if I were a lawyer in that deal, it would have certainly have been for us, which is there's a big regulatory component to the infusion therapy space. So obviously any healthcare industry, any private equity investor in healthcare, has to understand the regulatory environment across the board. But in that subsector and infusion therapy particularly has some real hot button issues because these are stark services. So they're heavily regulated and there are a lot of physician relationships and referral sources in there. So I am guessing that the lawyers that worked on that deal diligenced it pretty hard, including from the lender side, etc.

[B]

Fascinating to hear. And you're right, there was a frenetic crazy phase. 2021, 22 now busy, but not insane, but busy. And people looking at lots of different places to put money in health care, private equity. And fascinating to see it move into technology. Infusion services still in surgery centers, lots in pharma, lots in other areas, and still some of the practice area too. I mean that hasn't stopped. It's changed some, but it hasn't stopped.

[C]

That's right. And you mentioned the practice area. That's the other interesting feature about infusion therapy is that the Helix deal involved freestanding centers and then they have this model of managing physician owned centers. Well, you see infusion as an ancillary service in a lot of PPM businesses. And so this is one of the places where you see a point of connection between physician practice management businesses, especially those that are high infusion, like oncology or GI or rheumatology or immunology, and then connected to the separate private equity backed infusion platform. So you see this come up in a lot of areas similar to the ambulatory surgery center sector, which is it can be a freestanding business just of ASCs or an ASC can be a really important part of a PPM strategy. Right.

[B]

You also saw things like Cardinal Health by a big oncology platform too that had a combination of physicians and infusion too, right?

[C]

Yes, absolutely.

[B]

So, so you do see a lot of these different evolutions of things where there's physicians and infusion and ancillaries, infusion being the ancillary. But, but lots of opportunities. Fascinating. Fascinating. Fascinating. Amber, anything else you want to share about this deal? And so this evolution, you know, but, but your, your point is so well taken. This isn't just ambulatory infusion. It's ambulatory infusion and physician practice management, even if staged in a slightly different way.

[C]

Yeah, that's right. And I just think I really enjoy seeing these announcements come out, seeing what I think of as kind of a classic deal. A classic deal where you have private equity on both sides. You have seen scale happen by both the buyer and the seller prior to the deal happening. It has a lot of features that, you know, private equity investors are looking at when they're growing a platform, selling a platform, hoping that it's going to be able to achieve what it needs to achieve. And then there's pieces of it, of course, that I don't know since I wasn't part of the deal. But I've got to think there was heavy diligence not just on those referral relationships, but on supply chain and drug costs and all of these things. It just really comes back to this is kind of a quintessential, from what I can tell as an outsider, kind of a quintessential private equity backed by deal in a space that's really popular right now and therefore I think is worth talking about.

[B]

Couldn't agree more. Amber. I want to thank you as always for joining us on the Becker Business, the Becker Private equity podcast. You are as good a leader as they come. The very best. Thank you for being with us today.

[C]

Thank you, Scott.

[A]

The 2026 FIFA World cup meal at McDonald's is underway with one of nine Legends Legendary Cups in the lineup. Christian Pulisic, David Beckham, Lamino Mall, Ronaldinho, Thierry Henry, Son Hyung Min, Alfonso Davies, Santi Jimenez. And between the posts, it's Grimace. Get one of nine collectible cups with a FIFA World cup meal at participating McDonald's for a limited time while supplies last all rights reserve 2026 McDonald's at FIFA World Cup 2026.